By Fineline Cube WuXi ATU, the gene and cell therapy-focused CTDMO unit of WuXi Apptec (SHA: 603259, HKG: 2359), has formed a partnership with US clinical biotech firm Wugen, Inc. This collaboration centers on Wugen’s immunotherapy candidate WU-NK-101, with WuXi ATU providing Good Manufacturing Practice (GMP)-compliant manufacturing and testing services to support regulatory filings and clinical trials.
Collaboration Details
WuXi ATU will leverage its expertise to accelerate the research and development of Wugen’s WU-NK-101, an “off-the-shelf” immune memory natural killer (NK) cell therapy. This therapy is developed using Wugen’s proprietary Moneta platform and is currently in the pre-clinical stage. The partnership aims to advance the candidate into clinical studies for severe acute myeloid leukemia (AML) and other solid tumors.
Wugen’s Focus
Wugen specializes in developing NK cell therapies and CAR-T cell therapies for hematological and solid malignancies. The company’s lead program, WU-NK-101, represents a novel approach to cancer treatment by utilizing allogeneic NK cells engineered to have immune memory capabilities.-Fineline Info & Tech